Publicada a RDC Anvisa n. 395 que altera a Resolução de Diretoria Colegiada RDC n° 352, de 20 de março de 2020, que dispõe sobre a autorização prévia para fins de exportação de matéria-prima, produto semi-elaborado, produto a granel ou produto farmacêutico acabado destinados ao combate da COVID-19 / RDC Anvisa n. 395 that alters Collegiate Board Resolution - RDC No. 352, of March 20, 2020, which provides for prior authorization for the purpose of exporting raw materials, semi-finished products, bulk products or finished pharmaceutical products for the COVID-19 combat
Brasília; CONASS; jun. 2020. (CONASS informa, 266).
Monography
in Portuguese
| CONASS, LILACS
| ID: biblio-1100543
Responsible library:
BR1.1
Subject(s)
Full text:
Available
Collection:
International databases
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
/
SDG3 - Target 3.3 End transmission of communicable diseases
Health problem:
Goal 4: Health financing
/
Target 3.3: End transmission of communicable diseases
/
Pneumonia
Database:
CONASS
/
LILACS
Main subject:
Pneumonia, Viral
/
Quarantine
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
Language:
Portuguese
Journal:
CONASS informa
Year:
2020
Document type:
Monography
